RZLT — Rezolute Inc · catalysts, narrative & risks

Snapshot (as of the research date, ~2026-10-30/31)

Rezolute, Inc. (Nasdaq: RZLT) is a late-stage/clinical-stage rare-disease biopharmaceutical company headquartered in Redwood City, California, led by CEO Nevan Elam [6], [12], [14]. Its lead asset is ersodetug (RZ358), a fully human monoclonal antibody that binds an allosteric site on the insulin receptor to reduce the effects of excessive insulin; it is being developed for congenital HI and tumor HI [8], [12], [14]. A secondary candidate, RZ402 (oral plasma kallikrein inhibitor for retinal vascular disease, e.g., diabetic macular edema), exists but is lower in the pipeline [12].